Conformational Bias: A key concept for protein kinase inhibition

European Pharmaceutical Review

Volumn 17, Issue 1, 2012, Pages

  Möbitz, Henrik ^a   Fabbro, Doriano ^b  

^a Novartis Institutes for Biomedical Research   (United States)

^b Novartis Institutes for Biomedical Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; VEMURAFENIB;

ARTICLE; BETA SHEET; BINDING KINETICS; BINDING SITE; CONFORMATIONAL TRANSITION; DOWN REGULATION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME BINDING; ENZYME CONFORMATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; LIGAND BINDING; MOLECULAR WEIGHT;

EID: 84876211993     PISSN: 13608606     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Article

References (112)

1. P. Blume-Jensen, T. Hunter, Oncogenic kinase signalling, Nature 411 (2001) 355-365
2. C.-J.S. Fabbro D, Möbitz H, Martiny-Baron G., Targeting cancer with small-molecular-weight kinase inhibitors, Methods Mol Biol 795 (2012) 1-34
3. C. Garcia-Echeverria, Protein and lipid kinase inhibitors as targeted anticancer agents of the Ras/Raf/MEK and PI3K/PKB pathways, Purinergic Signal 5 (2009) 117-125
4. L.K. Chico, L.J. Van Eldik, D.M. Watterson, Targeting protein kinases in central nervous system disorders, Nat Rev Drug Discov 8 (2009) 892-909
5. C. Garcia-Echeverria, W.R. Sellers, Drug discovery approaches targeting the PI3K/Akt pathway in cancer, Oncogene 27 (2008) 5511-5526
6. S.M. Maira, C. Voliva, C. Garcia-Echeverria, Class IA phosphatidylinositol 3-kinase: from their biologic implication in human cancers to drug discovery, Expert Opin Ther Targets 12 (2008) 223-238
7. T.L. Yuan, L.C. Cantley, PI3K pathway alterations in cancer: variations on a theme, Oncogene 27 (2008) 5497-5510
8. M. Malumbres, M. Barbacid, Cell cycle, CDKs and cancer: a changing paradigm, Nat Rev Cancer 9 (2009) 153-166
9. J. Luo, N.L. Solimini, S.J. Elledge, Principles of cancer therapy: oncogene and non-oncogene addiction, Cell 136 (2009) 823-837
10. I.B. Weinstein, Cancer. Addiction to oncogenes-the Achilles heal of cancer, Science 297 (2002) 63-64
11. W.R. Sellers, A blueprint for advancing genetics-based cancer therapy, Cell 147 (2011) 26-31
12. D. Fabbro, Fendrich, G., Guez V, Meyer T, Furet P, Mestan P, Griffin JD, Manley PW, Cowan-JacobSW, Targeted therapy with imatinib: An exception or a rule?, Handbook of Experimental Pharmacology, Inhibitors of Protein Kinases and Protein Phosphates 167 (2005) 361-389
13. W. Pao, V.A. Miller, K.A. Politi, G.J. Riely, R. Somwar, M.F. Zakowski, M.G. Kris, H. Varmus, Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain, PLoS Med 2 (2005) e73
14. C. Sawyers, Targeted cancer therapy, Nature 432 (2004) 294-297
15. A. Bardelli, D.W. Parsons, N. Silliman, J. Ptak, S. Szabo, S. Saha, S. Markowitz, J.K. Willson, G. Parmigiani, K.W. Kinzler, B. Vogelstein, V.E. Velculescu, Mutational analysis of the tyrosine kinome in colorectal cancers, Science 300 (2003) 949
16. C. Greenman, P. Stephens, R. Smith, G.L. Dalgliesh, C. Hunter, G. Bignell, H. Davies, J. Teague, A. Butler, C. Stevens, S. Edkins, S. O'Meara, I. Vastrik, E.E. Schmidt, T. Avis, S. Barthorpe, G. Bhamra, G. Buck, B. Choudhury, J. Clements, J. Cole, E. Dicks, S. Forbes, K. Gray, K. Halliday, R. Harrison, K. Hills, J. Hinton, A. Jenkinson, D. Jones, A. Menzies, T. Mironenko, J. Perry, K. Raine, D. Richardson, R. Shepherd, A. Small, C. Tofts, J. Varian, T. Webb, S. West, S. Widaa, A. Yates, D.P. Cahill, D.N. Louis, P. Goldstraw, A.G. Nicholson, F. Brasseur, L. Looijenga, B.L. Weber, Y.E. Chiew, A. DeFazio, M.F. Greaves, A.R. Green, P. Campbell, E. Birney, D.F. Easton, G. Chenevix-Trench, M.H. Tan, S.K. Khoo, B.T. Teh, S.T. Yuen, S.Y. Leung, R. Wooster, P.A. Futreal, M.R. Stratton, Patterns of somatic mutation in human cancer genomes, Nature 446 (2007) 153-158
17. R.K. Thomas, A.C. Baker, R.M. Debiasi, W. Winckler, T. Laframboise, W.M. Lin, M. Wang, W. Feng, T. Zander, L. MacConaill, J.C. Lee, R. Nicoletti, C. Hatton, M. Goyette, L. Girard, K. Majmudar, L. Ziaugra, K.K. Wong, S. Gabriel, R. Beroukhim, M. Peyton, J. Barretina, A. Dutt, C. Emery, H. Greulich, K. Shah, H. Sasaki, A. Gazdar, J. Minna, S.A. Armstrong, I.K. Mellinghoff, F.S. Hodi, G. Dranoff, P.S. Mischel, T.F. Cloughesy, S.F. Nelson, L.M. Liau, K. Mertz, M.A. Rubin, H. Moch, M. Loda, W. Catalona, J. Fletcher, S. Signoretti, F. Kaye, K.C. Anderson, G.D. Demetri, R. Dummer, S. Wagner, M. Herlyn, W.R. Sellers, M. Meyerson, L.A. Garraway, High-throughput oncogene mutation profiling in human cancer, Nat Genet 39 (2007) 347-351
18. S.S. Taylor, A.P. Kornev, Protein kinases: evolution of dynamic regulatory proteins, Trends Biochem Sci 36 (2011) 65-77
19. P. Lahiry, A. Torkamani, N.J. Schork, R.A. Hegele, Kinase mutations in human disease: interpreting genotypephenotype relationships, Nat Rev Genet 11 (2010) 60-74
20. P. Cohen, Protein kinases-the major drug targets of the twenty-first century?, Nat Rev Drug Discov 1 (2002) 309- 315
21. M. Vieth, R.E. Higgs, D.H. Robertson, M. Shapiro, E.A. Gragg, H. Hemmerle, Kinomics-structural biology and chemogenomics of kinase inhibitors and targets, Biochim Biophys Acta 1697 (2004) 243-257
22. A. Wolf-Yadlin, N. Kumar, Y. Zhang, S. Hautaniemi, M. Zaman, H.D. Kim, V. Grantcharova, D.A. Lauffenburger, F.M. White, Effects of HER2 overexpression on cell signaling networks governing proliferation and migration, Mol Syst Biol 2 (2006) 54
23. J.G. Paez, P.A. Janne, J.C. Lee, S. Tracy, H. Greulich, S. Gabriel, P. Herman, F.J. Kaye, N. Lindeman, T.J. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M.J. Eck, W.R. Sellers, B.E. Johnson, M. Meyerson, EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy, Science 304 (2004) 1497-1500
24. W. Zhou, D. Ercan, L. Chen, C.H. Yun, D. Li, M. Capelletti, A.B. Cortot, L. Chirieac, R.E. Iacob, R. Padera, J.R. Engen, K.K. Wong, M.J. Eck, N.S. Gray, P.A. Janne, Novel mutantselective EGFR kinase inhibitors against EGFR T790M, Nature 462 (2009) 1070-1074
25. M.C. Heinrich, C.L. Corless, G.D. Demetri, C.D. Blanke, M. von Mehren, H. Joensuu, L.S. McGreevey, C.J. Chen, A.D. Van den Abbeele, B.J. Druker, B. Kiese, B. Eisenberg, P.J. Roberts, S. Singer, C.D. Fletcher, S. Silberman, S. Dimitrijevic, J.A. Fletcher, Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor, J Clin Oncol 21 (2003) 4342-4349
26. T.J. Lynch, D.W. Bell, R. Sordella, S. Gurubhagavatula, R.A. Okimoto, B.W. Brannigan, P.L. Harris, S.M. Haserlat, J.G. Supko, F.G. Haluska, D.N. Louis, D.C. Christiani, J. Settleman, D.A. Haber, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib, N Engl J Med 350 (2004) 2129-2139
27. M.E. Gorre, M. Mohammed, K. Ellwood, N. Hsu, R. Paquette, P.N. Rao, C.L. Sawyers, Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification, Science 293 (2001) 876-880
28. S. Kobayashi, T.J. Boggon, T. Dayaram, P.A. Janne, O. Kocher, M. Meyerson, B.E. Johnson, M.J. Eck, D.G. Tenen, B. Halmos, EGFR mutation and resistance of non-smallcell lung cancer to gefitinib, N Engl J Med 352 (2005) 786-792
29. T. Hunter, Signaling-2000 and beyond, Cell 100 (2000) 113-127
30. J.J. Ventura, A.R. Nebreda, Protein kinases and phosphatases as therapeutic targets in cancer, Clin Transl Oncol 8 (2006) 153-160
31. J.A. Engelman, K. Zejnullahu, T. Mitsudomi, Y. Song, C. Hyland, J.O. Park, N. Lindeman, C.M. Gale, X. Zhao, J. Christensen, T. Kosaka, A.J. Holmes, A.M. Rogers, F. Cappuzzo, T. Mok, C. Lee, B.E. Johnson, L.C. Cantley, P.A. Janne, MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling, Science 316 (2007) 1039-1043
32. T. Takano, Y. Ohe, H. Sakamoto, K. Tsuta, Y. Matsuno, U. Tateishi, S. Yamamoto, H. Nokihara, N. Yamamoto, I. Sekine, H. Kunitoh, T. Shibata, T. Sakiyama, T. Yoshida, T. Tamura, Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent nonsmallcell lung cancer, J Clin Oncol 23 (2005) 6829-6837
33. S. Ali, S. Ali, Role of c-kit/SCF in cause and treatment of gastrointestinal stromal tumors (GIST), Gene 401 (2007) 38-45
34. S. Chandarlapaty, A. Sawai, M. Scaltriti, V. Rodrik- Outmezguine, O. Grbovic-Huezo, V. Serra, P.K. Majumder, J. Baselga, N. Rosen, AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity, Cancer Cell 19 (2011) 58-71
35. J.A. Engelman, L. Chen, X. Tan, K. Crosby, A.R. Guimaraes, R. Upadhyay, M. Maira, K. McNamara, S.A. Perera, Y. Song, L.R. Chirieac, R. Kaur, A. Lightbown, J. Simendinger, T. Li, R.F. Padera, C. Garcia-Echeverria, R. Weissleder, U. Mahmood, L.C. Cantley, K.K. Wong, Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers, Nat Med 14 (2008) 1351-1356
36. E. Weisberg, P.W. Manley, W. Breitenstein, J. Bruggen, S.W. Cowan-Jacob, A. Ray, B. Huntly, D. Fabbro, G. Fendrich, E. Hall-Meyers, A.L. Kung, J. Mestan, G.Q. Daley, L. Callahan, L. Catley, C. Cavazza, M. Azam, D. Neuberg, R.D. Wright, D.G. Gilliland, J.D. Griffin, Characterization of AMN107, a selective inhibitor of native and mutant Bcr- Abl, Cancer Cell 7 (2005) 129-141
37. A. Quintas-Cardama, H. Kantarjian, J. Cortes, Flying under the radar: the new wave of BCR-ABL inhibitors, Nat Rev Drug Discov 6 (2007) 834-848
38. F.J. Adrian, Q. Ding, T. Sim, A. Velentza, C. Sloan, Y. Liu, G. Zhang, W. Hur, S. Ding, P. Manley, J. Mestan, D. Fabbro, N.S. Gray, Allosteric inhibitors of Bcr-abl-dependent cell proliferation, Nat Chem Biol 2 (2006) 95-102
39. L.J. Lombardo, F.Y. Lee, P. Chen, D. Norris, J.C. Barrish, K. Behnia, S. Castaneda, L.A. Cornelius, J. Das, A.M. Doweyko, C. Fairchild, J.T. Hunt, I. Inigo, K. Johnston, A. Kamath, D. Kan, H. Klei, P. Marathe, S. Pang, R. Peterson, S. Pitt, G.L. Schieven, R.J. Schmidt, J. Tokarski, M.L. Wen, J. Wityak, R.M. Borzilleri, Discovery of N-(2-chloro-6- methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1- yl)-2-methylpyrimidin-4-ylamino) thiazole-5- carboxami de (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays, J Med Chem 47 (2004) 6658-6661
40. J. Zhang, Adrian, F.J., Jahnke, W., Cowan-Jacob, S.W., Li,A.G., Iacob, R.E., Sim, T.,Powers, J., Dierks, C., Sun, F., Guo, G.R., Ding, Q., Okram, B., Choi, Y.,Wojciechowski, A., Deng, X., Liu, G., Fendrich, G., Strauss, A., Vajpai, N., Grzesiek, S., Tuntland, T., Liu, Y., Bursulaya, B., Azam, M., Manley, P.W., Engen, J.R., Daley, G.Q., Warmuth, M., Gray, N.S., Targeting wild-type and T315I Bcr-Abl by combining allosteric with ATP-site inhibitors, Nature Chem. Biol. in press (2009)
41. S.K. Hanks, T. Hunter, Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification, Faseb J 9 (1995) 576-596
42. M. Vieth, J.J. Sutherland, D.H. Robertson, R.M. Campbell, Kinomics: characterizing the therapeutically validated kinase space, Drug Discov Today 10 (2005) 839-846
43. A. Levitzki, Protein kinase inhibitors as a therapeutic modality, Acc Chem Res 36 (2003) 462-469
44. D. Fabbro, C. Garcia-Echeverria, Targeting protein kinases in cancer therapy, Curr Opin Drug Discov Devel 5 (2002) 701-712
45. S.W. Cowan-Jacob, Structural biology of protein tyrosine kinases, Cell Mol Life Sci 63 (2006) 2608-2625
46. S.R. Hubbard, Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog, Embo J 16 (1997) 5572-5581
47. D.O. Morgan, The dynamics of cyclin dependent kinase structure, Curr Opin Cell Biol 8 (1996) 767-772
48. K. Niefind, J. Raaf, O.G. Issinger, Protein kinase CK2 in health and disease: Protein kinase CK2: from structures to insights, Cell Mol Life Sci 66 (2009) 1800-1816
49. Madhusudan, P. Akamine, N.H. Xuong, S.S. Taylor, Crystal structure of a transition state mimic of the catalytic subunit of cAMP-dependent protein kinase, Nat Struct Biol 9 (2002) 273-277
50. D. Fabbro, S.W. Cowan-Jacob, H. Mobitz, G. Martiny- Baron, Targeting cancer with small-molecular-weight kinase inhibitors, Methods Mol Biol 795 (2011) 1-34
51. J.A. Fletcher, B.P. Rubin, KIT mutations in GIST, Curr Opin Genet Dev 17 (2007) 3-7
52. S. Manie, M. Santoro, A. Fusco, M. Billaud, The RET receptor: function in development and dysfunction in congenital malformation, Trends Genet 17 (2001) 580-589
53. P. Traxler, G. Bold, E. Buchdunger, G. Caravatti, P. Furet, P. Manley, T. O'Reilly, J. Wood, J. Zimmermann, Tyrosine kinase inhibitors: from rational design to clinical trials, Med Res Rev 21 (2001) 499-512
54. J. Zhang, Yang, P. L., Gray, N. S., Targeting cancer with small molecule kinase inhibitors, Nat Rev Cancer 9 (2009) 28-39
55. B. Li, Y. Liu, T. Uno, N. Gray, Creating chemical diversity to target protein kinases, Comb Chem High Throughput Screen 7 (2004) 453-472
56. F. Zuccotto, E. Ardini, E. Casale, M. Angiolini, Through the "gatekeeper door": exploiting the active kinase conformation, J Med Chem 53 (2010) 2681-2694
57. D. Vanderpool, T.O. Johnson, C. Ping, S. Bergqvist, G. Alton, S. Phonephaly, E. Rui, C. Luo, Y.L. Deng, S. Grant, T. Quenzer, S. Margosiak, J. Register, E. Brown, J. Ermolieff, Characterization of the CHK1 allosteric inhibitor binding site, Biochemistry 48 (2009) 9823-9830
58. Y. Liu, Gray, N. S., Rational design of inhibitors that bind to inactive kinase conformations, Nat Chem Biol 2 (2006) 358-364
59. Y. Blat, Non-competitive inhibition by active site binders, Chem Biol Drug Des 75 (2010) 535-540
60. J.F. Ohren, H. Chen, A. Pavlovsky, C. Whitehead, E. Zhang, P. Kuffa, C. Yan, P. McConnell, C. Spessard, C. Banotai, W.T. Mueller, A. Delaney, C. Omer, J. Sebolt-Leopold, D.T. Dudley, I.K. Leung, C. Flamme, J. Warmus, M. Kaufman, S. Barrett, H. Tecle, C.A. Hasemann, Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition, Nat Struct Mol Biol 11 (2004) 1192-1197
61. D. Fabbro, Manley, P.W., Jahnke, W., Liebetanz, J., Szyttenholm, A., Fendrich, G., Strauss, A., Zhang, J., Gray, N.S., Adrian, F., Warmuth, M., Pelle, X., Grotzfeld, R., Berst, F., Marzinzik, A., Furet, P., Cowan-Jacob, S.W., Mestan, J., Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site Biochem Biophys Acta in press. (2010)
62. N. Vajpai, A. Strauss, G. Fendrich, S.W. Cowan-Jacob, P.W. Manley, S. Grzesiek, W. Jahnke, Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib, J Biol Chem 283 (2008) 18292-18302
63. I. Kufareva, R. Abagyan, Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states, J Med Chem 51 (2008) 7921-7932
64. Y. Shan, M.A. Seeliger, M.P. Eastwood, F. Frank, H. Xu, M.O. Jensen, R.O. Dror, J. Kuriyan, D.E. Shaw, A conserved protonation-dependent switch controls drug binding in the Abl kinase, Proc Natl Acad Sci U S A 106 (2009) 139-144
65. A.C. Dar, M.S. Lopez, K.M. Shokat, Small molecule recognition of c-Src via the Imatinib-binding conformation, Chem Biol 15 (2008) 1015-1022
66. M.A. Seeliger, P. Ranjitkar, C. Kasap, Y. Shan, D.E. Shaw, N.P. Shah, J. Kuriyan, D.J. Maly, Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations, Cancer Res 69 (2009) 2384-2392
67. D.R. Anderson, M.J. Meyers, R.G. Kurumbail, N. Caspers, G.I. Poda, S.A. Long, B.S. Pierce, M.W. Mahoney, R.J. Mourey, Benzothiophene inhibitors of MK2. Part 1: structure-activity relationships, assessments of selectivity and cellular potency, Bioorg Med Chem Lett 19 (2009) 4878-4881
68. D.R. Anderson, M.J. Meyers, R.G. Kurumbail, N. Caspers, G.I. Poda, S.A. Long, B.S. Pierce, M.W. Mahoney, R.J. Mourey, M.D. Parikh, Benzothiophene inhibitors of MK2. Part 2: improvements in kinase selectivity and cell potency, Bioorg Med Chem Lett 19 (2009) 4882-4884
69. D. Casper, M. Bukhtiyarova, E.B. Springman, A Biacore biosensor method for detailed kinetic binding analysis of small molecule inhibitors of p38alpha mitogenactivated protein kinase, Anal Biochem 325 (2004) 126- 136
70. P.J. Tummino, R.A. Copeland, Residence time of receptor-ligand complexes and its effect on biological function, Biochemistry 47 (2008) 5481-5492
71. D.C. Swinney, The role of binding kinetics in therapeutically useful drug action, Curr Opin Drug Discov Devel 12 (2009) 31-39
72. R.A. Copeland, D.L. Pompliano, T.D. Meek, Drug-target residence time and its implications for lead optimization, Nat Rev Drug Discov 5 (2006) 730-739.
73. R. Morphy, Z. Rankovic, Fragments, network biology and designing multiple ligands, Drug Discov Today 12 (2007) 156-160
74. M.W. Karaman, S. Herrgard, D.K. Treiber, P. Gallant, C.E. Atteridge, B.T. Campbell, K.W. Chan, P. Ciceri, M.I. Davis, P.T. Edeen, R. Faraoni, M. Floyd, J.P. Hunt, D.J. Lockhart, Z.V. Milanov, M.J. Morrison, G. Pallares, H.K. Patel, S. Pritchard, L.M. Wodicka, P.P. Zarrinkar, A quantitative analysis of kinase inhibitor selectivity, Nat Biotechnol 26 (2008) 127-132
75. Z.A. Knight, K.M. Shokat, Features of selective kinase inhibitors, Chem Biol 12 (2005) 621-637
76. M.A. Fabian, W.H. Biggs, 3rd, D.K. Treiber, C.E. Atteridge, M.D. Azimioara, M.G. Benedetti, T.A. Carter, P. Ciceri, P.T. Edeen, M. Floyd, J.M. Ford, M. Galvin, J.L. Gerlach, R.M. Grotzfeld, S. Herrgard, D.E. Insko, M.A. Insko, A.G. Lai, J.M. Lelias, S.A. Mehta, Z.V. Milanov, A.M. Velasco, L.M. Wodicka, H.K. Patel, P.P. Zarrinkar, D.J. Lockhart, A small molecule-kinase interaction map for clinical kinase inhibitors, Nat Biotechnol 23 (2005) 329-336
77. M.I. Davis, J.P. Hunt, S. Herrgard, P. Ciceri, L.M. Wodicka, G. Pallares, M. Hocker, D.K. Treiber, P.P. Zarrinkar, Comprehensive analysis of kinase inhibitor selectivity, Nat Biotechnol 29 (2011) 1046-1051
78. T. Anastassiadis, S.W. Deacon, K. Devarajan, H. Ma, J.R. Peterson, Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity, Nat Biotechnol 29 (2011) 1039-1045
79. K. West, CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders, Curr Opin Investig Drugs 10 (2009) 491-504
80. A. Converso, T. Hartingh, R.M. Garbaccio, E. Tasber, K. Rickert, M.E. Fraley, Y. Yan, C. Kreatsoulas, S. Stirdivant, B. Drakas, E.S. Walsh, K. Hamilton, C.A. Buser, X. Mao, M.T. Abrams, S.C. Beck, W. Tao, R. Lobell, L. Sepp-Lorenzino, J. Zugay-Murphy, V. Sardana, S.K. Munshi, S.M. Jezequel- Sur, P.D. Zuck, G.D. Hartman, Development of thioquinazolinones, allosteric Chk1 kinase inhibitors, Bioorg Med Chem Lett 19 (2009) 1240-1244
81. H. Tecle, J. Shao, Y. Li, M. Kothe, S. Kazmirski, J. Penzotti, Y.H. Ding, J. Ohren, D. Moshinsky, R. Coli, N. Jhawar, E. Bora, S. Jacques-O'Hagan, J. Wu, Beyond the MEKpocket: can current MEK kinase inhibitors be utilized to synthesize novel type III NCKIs? Does the MEK-pocket exist in kinases other than MEK?, Bioorg Med Chem Lett 19 (2009) 226-229
82. T. Fox, J.T. Coll, X. Xie, P.J. Ford, U.A. Germann, M.D. Porter, S. Pazhanisamy, M.A. Fleming, V. Galullo, M.S. Su, K.P. Wilson, A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase, Protein Sci 7 (1998) 2249-2255
83. M. Fricker, P. Lograsso, S. Ellis, N. Wilkie, P. Hunt, S.J. Pollack, Substituting c-Jun N-terminal kinase-3 (JNK3) ATP-binding site amino acid residues with their p38 counterparts affects binding of JNK- and p38- selective inhibitors, Arch Biochem Biophys 438 (2005) 195-205
84. M. Kothe, D. Kohls, S. Low, R. Coli, A.C. Cheng, S.L. Jacques, T.L. Johnson, C. Lewis, C. Loh, J. Nonomiya, A.L. Sheils, K.A. Verdries, T.A. Wynn, C. Kuhn, Y.H. Ding, Structure of the catalytic domain of human polo-like kinase 1, Biochemistry 46 (2007) 5960-5971
85. S.F. Bellon, P. Kaplan-Lefko, Y. Yang, Y. Zhang, J. Moriguchi, K. Rex, C.W. Johnson, P.E. Rose, A.M. Long, A.B. O'Connor, Y. Gu, A. Coxon, T.S. Kim, A. Tasker, T.L. Burgess, I. Dussault, c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations, J Biol Chem 283 (2008) 2675-2683
86. I. Dussault, S.F. Bellon, c-Met inhibitors with different binding modes: two is better than one, Cell Cycle 7 (2008) 1157-1160
87. E.R. Wood, A.T. Truesdale, O.B. McDonald, D. Yuan, A. Hassell, S.H. Dickerson, B. Ellis, C. Pennisi, E. Horne, K. Lackey, K.J. Alligood, D.W. Rusnak, T.M. Gilmer, L. Shewchuk, A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor offrate, and receptor activity in tumor cells, Cancer Res 64 (2004) 6652-6659
88. T. Schindler, W. Bornmann, P. Pellicena, W.T. Miller, B. Clarkson, J. Kuriyan, Structural mechanism for STI- 571 inhibition of abelson tyrosine kinase, Science 289 (2000) 1938-1942
89. B.K. Albrecht, J.C. Harmange, D. Bauer, L. Berry, C. Bode, A.A. Boezio, A. Chen, D. Choquette, I. Dussault, C. Fridrich, S. Hirai, D. Hoffman, J.F. Larrow, P. Kaplan-Lefko, J. Lin, J. Lohman, A.M. Long, J. Moriguchi, A. O'Connor, M.H. Potashman, M. Reese, K. Rex, A. Siegmund, K. Shah, R. Shimanovich, S.K. Springer, Y. Teffera, Y. Yang, Y. Zhang, S.F. Bellon, Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase, J Med Chem 51 (2008) 2879-2882
90. N.K. Williams, R.S. Bamert, O. Patel, C. Wang, P.M. Walden, A.F. Wilks, E. Fantino, J. Rossjohn, I.S. Lucet, Dissecting specificity in the Janus kinases: the structures of JAKspecific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains, J Mol Biol 387 (2009) 219-232
91. E.L. Kwak, R. Sordella, D.W. Bell, N. Godin-Heymann, R.A. Okimoto, B.W. Brannigan, P.L. Harris, D.R. P. Fidias, T.J. Lynch, S.K. Rabindran, J.P. McGinnis, A. Wissner, S.V. Sharma, K.J. Isselbacher, J. Settleman, D.A. Haber, Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib, Proc Natl Acad Sci U S A 102 (2005) 7665-7670
92. M. Azam, M.A. Seeliger, N.S. Gray, J. Kuriyan, G.Q. Daley, Activation of tyrosine kinases by mutation of the gatekeeper threonine, Nat Struct Mol Biol 15 (2008) 1109-1118
93. N.J. Dibb, S.M. Dilworth, C.D. Mol, Switching on kinases: oncogenic activation of BRAF and the PDGFR family, Nat Rev Cancer 4 (2004) 718-727
94. A.P. Kornev, N.M. Haste, S.S. Taylor, L.F. Eyck, Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism, Proc Natl Acad Sci U S A 103 (2006) 17783-17788
95. H. Kantarjian, F. Giles, L. Wunderle, K. Bhalla, S. O'Brien, B. Wassmann, C. Tanaka, P. Manley, P. Rae, W. Mietlowski, K. Bochinski, A. Hochhaus, J.D. Griffin, D. Hoelzer, M. Albitar, M. Dugan, J. Cortes, L. Alland, O.G. Ottmann, Nilotinib in imatinib-resistant CML and Philadelphia chromosomepositive ALL, N Engl J Med 354 (2006) 2542-2551
96. H. Kantarjian, N.P. Shah, A. Hochhaus, J. Cortes, S. Shah, M. Ayala, B. Moiraghi, Z. Shen, J. Mayer, R. Pasquini, H. Nakamae, F. Huguet, C. Boque, C. Chuah, E. Bleickardt, M.B. Bradley-Garelik, C. Zhu, T. Szatrowski, D. Shapiro, M. Baccarani, Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia, N Engl J Med 362 (2010) 2260-2270
97. C.H. Yun, K.E. Mengwasser, A.V. Toms, M.S. Woo, H. Greulich, K.K. Wong, M. Meyerson, M.J. Eck, The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP, Proc Natl Acad Sci U S A 105 (2008) 2070-2075
98. T. O'Hare, W.C. Shakespeare, X. Zhu, C.A. Eide, V.M. Rivera, F. Wang, L.T. Adrian, T. Zhou, W.S. Huang, Q. Xu, C.A. Metcalf, 3rd, J.W. Tyner, M.M. Loriaux, A.S. Corbin, S. Wardwell, Y. Ning, J.A. Keats, Y. Wang, R. Sundaramoorthi, M. Thomas, D. Zhou, J. Snodgrass, L. Commodore, T.K. Sawyer, D.C. Dalgarno, M.W. Deininger, B.J. Druker, T. Clackson, AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance, Cancer Cell 16 (2009) 401-412
99. M.A. Lemmon, J. Schlessinger, Cell signaling by receptor tyrosine kinases, Cell 141 (2010) 1117-1134
100. M. Huse, J. Kuriyan, The conformational plasticity of protein kinases, Cell 109 (2002) 275-282
101. X. Zhang, J. Gureasko, K. Shen, P.A. Cole, J. Kuriyan, An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor, Cell 125 (2006) 1137-1149
102. V. Gray-Schopfer, C. Wellbrock, R. Marais, Melanoma biology and new targeted therapy, Nature 445 (2007) 851-857
103. G. Bollag, P. Hirth, J. Tsai, J. Zhang, P.N. Ibrahim, H. Cho, W. Spevak, C. Zhang, Y. Zhang, G. Habets, E.A. Burton, B. Wong, G. Tsang, B.L. West, B. Powell, R. Shellooe, A. Marimuthu, H. Nguyen, K.Y. Zhang, D.R. Artis, J. Schlessinger, F. Su, B. Higgins, R. Iyer, K. D'Andrea, A. Koehler, M. Stumm, P.S. Lin, R.J. Lee, J. Grippo, I. Puzanov, K.B. Kim, A. Ribas, G.A. McArthur, J.A. Sosman, P.B. Chapman, K.T. Flaherty, X. Xu, K.L. Nathanson, K. Nolop, Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma, Nature 467 (2010) 596-599
104. P.B. Chapman, A. Hauschild, C. Robert, J.B. Haanen, P. Ascierto, J. Larkin, R. Dummer, C. Garbe, A. Testori, M. Maio, D. Hogg, P. Lorigan, C. Lebbe, T. Jouary, D. Schadendorf, A. Ribas, S.J. O'Day, J.A. Sosman, J.M. Kirkwood, A.M. Eggermont, B. Dreno, K. Nolop, J. Li, B. Nelson, J. Hou, R.J. Lee, K.T. Flaherty, G.A. McArthur, Improved survival with vemurafenib in melanoma with BRAF V600E mutation, N Engl J Med 364 (2011) 2507- 2516
105. K.T. Flaherty, I. Puzanov, K.B. Kim, A. Ribas, G.A. McArthur, J.A. Sosman, P.J. O'Dwyer, R.J. Lee, J.F. Grippo, K. Nolop, P.B. Chapman, Inhibition of mutated, activated BRAF in metastatic melanoma, N Engl J Med 363 (2010) 809-819
106. N. Wagle, C. Emery, M.F. Berger, M.J. Davis, A. Sawyer, P. Pochanard, S.M. Kehoe, C.M. Johannessen, L.E. Macconaill, W.C. Hahn, M. Meyerson, L.A. Garraway, Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling, J Clin Oncol 29 (2011) 3085-3096
107. C.M. Johannessen, J.S. Boehm, S.Y. Kim, S.R. Thomas, L. Wardwell, L.A. Johnson, C.M. Emery, N. Stransky, A.P. Cogdill, J. Barretina, G. Caponigro, H. Hieronymus, R.R. Murray, K. Salehi-Ashtiani, D.E. Hill, M. Vidal, J.J. Zhao, X. Yang, O. Alkan, S. Kim, J.L. Harris, C.J. Wilson, V.E. Myer, P.M. Finan, D.E. Root, T.M. Roberts, T. Golub, K.T. Flaherty, R. Dummer, B.L. Weber, W.R. Sellers, R. Schlegel, J.A. Wargo, W.C. Hahn, L.A. Garraway, COT drives resistance to RAF inhibition through MAP kinase pathway reactivation, Nature 468 (2011) 968-972
108. R. Nazarian, H. Shi, Q. Wang, X. Kong, R.C. Koya, H. Lee, Z. Chen, M.K. Lee, N. Attar, H. Sazegar, T. Chodon, S.F. Nelson, G. McArthur, J.A. Sosman, A. Ribas, R.S. Lo, Melanomas acquire resistance to BRAF (V600E) inhibition by RTK or N-RAS upregulation, Nature 468 (2010) 973-977
109. P.I. Poulikakos, Y. Persaud, M. Janakiraman, X. Kong, C. Ng, G. Moriceau, H. Shi, M. Atefi, B. Titz, M.T. Gabay, M. Salton, K.B. Dahlman, M. Tadi, J.A. Wargo, K.T. Flaherty, M.C. Kelley, T. Misteli, P.B. Chapman, J.A. Sosman, T.G. Graeber, A. Ribas, R.S. Lo, N. Rosen, D.B. Solit, RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E), Nature 480 (2011) 387-390
110. C.M. Udell, T. Rajakulendran, F. Sicheri, M. Therrien, Mechanistic principles of RAF kinase signaling, Cell Mol Life Sci 68 (2011) 553-565
111. P.I. Poulikakos, C. Zhang, G. Bollag, K.M. Shokat, N. Rosen, RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF, Nature 464 (2010) 427-430
112. G. Hatzivassiliou, K. Song, I. Yen, B.J. Brandhuber, D.J. Anderson, R. Alvarado, M.J. Ludlam, D. Stokoe, S.L. Gloor, G. Vigers, T. Morales, I. Aliagas, B. Liu, S. Sideris, K.P. Hoeflich, B.S. Jaiswal, S. Seshagiri, H. Koeppen, M. Belvin, L.S. Friedman, S. Malek, RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth, Nature 464 (2010) 431-435